TY - JOUR
AU - Long, Merete B.
AU - Abo-Leyah, Hani
AU - Giam, Yan Hui
AU - Vadiveloo, Thenmalar
AU - Hull, Rebecca C.
AU - Keir, Holly R.
AU - Pembridge, Thomas
AU - De Lima, Daniela Alferes
AU - Delgado, Lilia
AU - Inglis, Sarah K.
AU - Hughes, Chloe
AU - Gilmour, Amy
AU - Gierlinski, Marek
AU - New, Benjamin J.M.
AU - MacLennan, Graeme
AU - Dinkova-Kostova, Albena T.
AU - Chalmers, James D.
PY - 2024
DA - January
TI - SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trial
JO - ERJ Open Research
VL - 10
IS - 2
DO - https://doi.org/10.1183/23120541.00917-2023
AB - Introduction Sulforaphane can induce the transcription factor, Nrf2, promoting antioxidant and anti-inflammatory responses. In this study, hospitalised patients with community-acquired pneumonia (CAP) were treated with stabilised synthetic sulforaphane (SFX-01) to evaluate impact on clinical status and inflammation.
PB - ERS Publications
UR - https://discovery.dundee.ac.uk/en/publications/594ce0fb-c7a9-4411-a5f2-d36fabd2225a
KW - Coronavirus (COVID-19)
KW - Hospital care
ER